Molecular imaging of atherosclerotic lesions by positron emission tomography - can it meet the expectations?

Abstract

Summary:Early non-invasive imaging of atherosclerosis and in particular the detection of lesions at risk with high specifi city could significantly affect cardiovascular morbidity and mortality. Conventional nuclear medicine approaches, in particular using autologous radiolabeled lipoproteins, can be related to histopathological fi ndings; however, they fail to identify lesions at risk. Positron emission tomography (PET) tracers with much better physical properties have been examined, the most detailed information being available for F-18-deoxyglucose (FDG) and F-18-sodium fl uoride (NaF). These two approaches are sensitive to different biochemical mechanisms, i.e. infl ammation and microcalcifi cation. Initial enthusiasm, in particular for F-18-FDG, has disappeared, although for F-18-NaF there is some hope, but this is not a breakthrough. No tracer is available so far that is able to identify a specifi c characteristic of a lesion prone to rupture. Other PET tracers in the pipeline have been examined, mainly in experimental models and only a few in patients, but they failed to contribute signifi cantly to early lesion discovery and do not support great expectations. The key question is: Do we understand what we see? Moreover, methodological problems, a lack of standardization of imaging protocols and aspects of quantifi cation provide a wide range for potential future improvements. While monitoring a therapeutic intervention seems to be possible for both F-18-FDG and F-18-NaF, highly specifi c early identifi cation of lesions at risk by PET imaging is still far away. As of today, PET is not ready for routine clinical judgment of atherosclerotic lesions at risk to rupture. Even if all these problems can be solved, radiation exposure will still remain a concern, in particular for repeated studies.

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study

“…Intensive statin therapy with atorvastatin at 80 mg daily has also been shown to both improve cardiovascular outcomes and reduce TBR better than lower-dose treatment with atorvastatin at 10 mg daily (Tawakol et al, 2013). Recent advances in the understanding of 18 FDG uptake have shown that the marker is also taken up by endothelial and smooth muscle cells, suggesting that its accumulation is dependent not only on vascular inflammation (Brammen et al, 2016). Studies using 18 FDG PET/CT have shown that vascular inflammation is increased in patients with psoriasis compared with age-and comorbidity-matched control subjects (Mehta et al, 2011;Naik et al, 2015;Rose et al, 2013).…”

Contrast-Enhanced, Molecular Imaging of Vascular Inflammation in the Mouse Model by Simultaneous PET/MRI

“…[12] Enthusiasm for the clinical use of 18 FDG to identify plaques has diminished over recent years with new tracers such as 18 NaF receiving greater attention; but specific imaging of plaque inflammation is still not available. [13] New, targeted imaging strategies that can identify inflamed plaques in smaller vessels, such as the coronary arteries, with higher specificity are needed.…”